Trial · NCT07458204
Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
NCT07458204, Phase 2, Not yet recruiting, Institut Jean-Godinot
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer. Trials, record NCT07458204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07458204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
- NCT number
- NCT07458204
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 760 participants, estimated
- Lead sponsor
- Institut Jean-Godinot
- Conditions
- Triple-negative Breast Cancer
- Interventions
- LVB infiltration
- First posted
- 2026-03-09
- Last updated
- 2026-03-09
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence free survival at 2 years | 2 years | time between breast surgery and the occurrence of the first recurrence (local, locoregional, or distant) or death from any cause. Patients living without recurrence at the end of follow-up will be censored at the endpoint (24 months after surgery). |
| Secondary | Overall survival at 2 years | 2 years | time between breast surgery and death from any cause. Patients living at the end of follow-up will be censored at the endpoint (24 months after surgery). |
| Secondary | Metastasis-free survival at 2 years | 2 years | time between breast surgery and the first metastasis. Patients without metastasis at the end of follow-up will be censored at the endpoint (24 months after surgery). |
| Secondary | Post-operative pain | 2 years | Postoperative pain assessed using a Visual Analogue Scale at 30 minutes, 2 hours, 6 hours and 24 hours after breast surgery then at 4 months, 8 months, 12 months, 16 months, 20 months and 24 months after breast surgery |
| Secondary | tolerance to levobupivacaine infiltration | 24 hours | occurrence of adverse effects: cardiac toxicity (arrhythmias, torsades de pointes) and allergy (skin symptoms, tachycardia, low blood pressure) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07458204
GET https://conductscience.org/api/trials/v1/NCT07458204/registered